Last $80.27 USD
Change Today -0.18 / -0.22%
Volume 13.5K
As of 10:17 AM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

heartware international inc (HTWR) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/14/14 - $105.84
52 Week Low
10/7/13 - $69.31
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

heartware international inc (HTWR) Related Businessweek News

No Related Businessweek News Found

heartware international inc (HTWR) Details

HeartWare International, Inc., a medical device company, is engaged in developing and manufacturing miniaturized implantable heart pumps or ventricular assist devices (VAD) for the treatment of advanced heart failure in the United States and internationally. The company offers HeartWare Ventricular Assist System, which includes a VAD, or blood pump, patient accessories, and surgical tools designed to provide circulatory support for patients in the advanced stage of heart failure. It is also developing the MVAD, a miniaturized blood pump, intended for chronic heart failure patients; and the SYNERGY Circulatory Support System, a partial support system designed to treat less sick, ambulatory, chronic heart failure patients who are not yet inotrope-dependent. In addition, HeartWare International, Inc. collaborates with Dualis MedTech GmbH for the development of an implantable system. The company markets its products directly to cardiac centers and hospitals, as well as through medical device distributors. HeartWare International, Inc. is headquartered in Framingham, Massachusetts.

569 Employees
Last Reported Date: 03/3/14

heartware international inc (HTWR) Top Compensated Officers

Chief Executive Officer, President, Managing ...
Total Annual Compensation: $541.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $324.8K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $331.6K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $329.2K
Senior Vice President of Sales and Marketing
Total Annual Compensation: $300.6K
Compensation as of Fiscal Year 2013.

heartware international inc (HTWR) Key Developments

HeartWare International, Inc. Appoints Katrin Leadley as Chief Medical Officer, Effective September 1, 2014

HeartWare International Inc. announced the appointment of Katrin Leadley, M.D., as Chief Medical Officer of HeartWare, effective September 1, 2014. Leadley brings to HeartWare extensive strategic leadership, with more than 20 years of clinical and industry experience at life sciences firms, including Quintiles, Boston Scientific Corporation and JenaValve Technology in Munich, where she spent the last three years as CMO leading the company's clinical, regulatory, scientific and medical activities.

Heartware International Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Heartware International Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue, net of $70,131,000 against $50,836,000 a year ago. Income from operations was $13,015,000 against loss from operations of $9,435,000 a year ago. Net income was $8,364,000 or $0.48 per diluted share against net loss of $12,934,000 or $0.79 per basic and diluted share a year ago. Non-GAAP adjusted net loss was $4,895,000 or $0.29 basic and diluted per share against $12,884,000 or $0.79 basic and diluted per share a year ago. Total operating expenses declined sequentially due to a $13.7 million reduction in the estimated fair value of the contingent consideration related to the CircuLite acquisition. This nonrecurring benefit was also the primary factor resulting in positive GAAP net income in the second quarter of 2014. During the second quarter, the company generated $5 million of positive operating cash flows, primarily as a result of AR collections boosted by strong preceding-quarter sales. For the six months, the company reported revenue, net of $136,603,000 against $100,075,000 a year ago. Loss from operations was $3,391,000 against $17,605,000 a year ago. Net loss was $11,080,000 or $0.65 per basic and diluted share against $17,605,000 or $1.66 per basic and diluted share a year ago. Non-GAAP adjusted net loss was $16,836,000 or $0.99 basic and diluted per share against $25,793,000 or $1.65 basic and diluted per share a year ago.

Heartware International Inc. to Report Q2, 2014 Results on Jul 31, 2014

Heartware International Inc. announced that they will report Q2, 2014 results at 11:00 PM, GMT Standard Time on Jul 31, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HTWR:US $80.27 USD -0.18

HTWR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ABIOMED Inc $24.93 USD -0.20
Getinge AB kr177.80 SEK +7.10
Sunshine Heart Inc $5.47 USD +0.04
Teleflex Inc $107.25 USD -0.23
Thoratec Corp $24.50 USD -0.105
View Industry Companies

Industry Analysis


Industry Average

Valuation HTWR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.6x
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEARTWARE INTERNATIONAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at